# Kratos

Type: Company (KTOS)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/kratos
Canonical HTML page: https://getbiobrief.com/entity/kratos

## Timeline

- **2026-02-23**: Earnings Release — Both companies report record Q4 results exceeding analyst guidance on revenue and EBITDA.
- **2026-Q1**: Debt Refinancing — BWXT completes $1.25B convertible debt raise to improve capital structure for 2026 expansion.
- **2025-12-31**: Fiscal Year End — BWXT Medical crosses $100M revenue threshold; Kratos hits record $1.57B backlog.

## Recent coverage (1 stories)

### BWXT Medical Hits $100M Milestone as Radiopharmaceutical Demand Surges
2026-02-24 02:27:41 · Sentiment: Positive · Impact: 6/10 · Sources: 2

BWXT Technologies reported record Q4 2025 results, highlighted by its medical segment surpassing the $100 million revenue threshold amid a global expansion in nuclear medicine. The company's strategic pivot toward radiopharmaceuticals, supported by a $1.25 billion debt refinancing, positions it as a critical infrastructure provider for the next generation of targeted cancer therapies.
Full story: https://getbiobrief.com/story/bwxt-medical-radiopharmaceutical-growth-2025

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.